{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:45:16Z","timestamp":1791229516996,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:00:00Z","timestamp":1697846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:00:00Z","timestamp":1697846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00417-023-06278-9","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T07:02:08Z","timestamp":1697871728000},"page":"457-468","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-term choroidal thickness changes based on the subtype of macular neovascularization in neovascular age-related macular degeneration (5-year follow-up)"],"prefix":"10.1007","volume":"262","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8190-7277","authenticated-orcid":false,"given":"Alaa Din","family":"Abdin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Hanifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wissam","family":"Aljundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shady","family":"Suffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,21]]},"reference":[{"issue":"6","key":"6278_CR1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.22608\/APO.2017251","volume":"6","author":"JB Jonas","year":"2017","unstructured":"Jonas JB, Cheung CMG, Panda-Jonas S (2017) Updates on the epidemiology of age-related macular degeneration. Asia Pac J Ophthalmol 6(6):493\u2013497. https:\/\/doi.org\/10.22608\/APO.2017251","journal-title":"Asia Pac J Ophthalmol"},{"issue":"6","key":"6278_CR2","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1517\/14728220902942322","volume":"13","author":"AJ Augustin","year":"2009","unstructured":"Augustin AJ, Kirchhof J (2009) Inflammation and the pathogenesis of age-related macular degeneration. Expert Opin Ther Targets 13(6):641\u2013651. https:\/\/doi.org\/10.1517\/14728220902942322","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"6278_CR3","doi-asserted-by":"publisher","first-page":"CD012208","DOI":"10.1002\/14651858.CD012208.pub2","volume":"5","author":"E Li","year":"2020","unstructured":"Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G (2020) Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev 5(5):CD012208. https:\/\/doi.org\/10.1002\/14651858.CD012208.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"6278_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00417-008-0952-y","volume":"247","author":"JS Schouten","year":"2009","unstructured":"Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F (2009) A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 247(1):1\u201311. https:\/\/doi.org\/10.1007\/s00417-008-0952-y","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6278_CR5","first-page":"91","volume":"92","author":"JD Gass","year":"1994","unstructured":"Gass JD (1994) Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Trans Am Ophthalmol Soc 92:91\u2013111 (discussion 111-6)","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"9","key":"6278_CR6","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/IAE.0b013e3181e7976b","volume":"30","author":"KB Freund","year":"2010","unstructured":"Freund KB, Zweifel SA, Engelbert M (2010) Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 30(9):1333\u20131349. https:\/\/doi.org\/10.1097\/IAE.0b013e3181e7976b","journal-title":"Retina"},{"issue":"9","key":"6278_CR7","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/s41433-022-02231-y","volume":"37","author":"T Mathis","year":"2023","unstructured":"Mathis T, Holz FG, Sivaprasad S, Yoon YH, Eter N, Chen LJ, Koh A, Cunha de Souza E, Staurenghi G (2023) Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes. Eye (Lond) 37(9):1758\u20131765. https:\/\/doi.org\/10.1038\/s41433-022-02231-y","journal-title":"Eye (Lond)"},{"issue":"5","key":"6278_CR8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, Waheed NK, Chakravarthy U, Rosenfeld PJ, Holz FG, Souied EH, Cohen SY, Querques G, Ohno-Matsui K, Boyer D, Gaudric A, Blodi B, Baumal CR, Li X, Coscas GJ, Brucker A, Singerman L, Luthert P, Schmitz-Valckenberg S, Schmidt-Erfurth U, Grossniklaus HE, Wilson DJ, Guymer R, Yannuzzi LA, Chew EY, Csaky K, Mon\u00e9s JM, Pauleikhoff D, Tadayoni R, Fujimoto J (2020) Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology 127(5):616\u2013636. https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.004","journal-title":"Ophthalmology"},{"issue":"4","key":"6278_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000310483","volume":"208","author":"A Giovannini","year":"1994","unstructured":"Giovannini A, Mariotti C, Ripa E, Scassellati B, Tittarelli R (1994) Choroidal filling in age-related macular degeneration: indocyanine green angiographic findings. Ophthalmologica 208(4):185\u2013191. https:\/\/doi.org\/10.1159\/000310483","journal-title":"Ophthalmologica"},{"issue":"4","key":"6278_CR10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.ajo.2014.12.025","volume":"159","author":"H Koizumi","year":"2015","unstructured":"Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Kawasaki R, Sekiryu T, Okada AA, Iida T (2015) Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. Am J Ophthalmol 159(4):627\u2013633. https:\/\/doi.org\/10.1016\/j.ajo.2014.12.025","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"6278_CR11","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.ophtha.2012.02.022","volume":"119","author":"T Yamazaki","year":"2012","unstructured":"Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S (2012) Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology 119(8):1621\u20131627. https:\/\/doi.org\/10.1016\/j.ophtha.2012.02.022","journal-title":"Ophthalmology"},{"key":"6278_CR12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2147\/OPTH.S30907","volume":"6","author":"AA Ellabban","year":"2012","unstructured":"Ellabban AA, Tsujikawa A, Ogino K, Ooto S, Yamashiro K, Oishi A, Yoshimura N (2012) Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization. Clin Ophthalmol 6:837\u2013844. https:\/\/doi.org\/10.2147\/OPTH.S30907","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"6278_CR13","first-page":"643","volume":"116","author":"M Ogasawara","year":"2012","unstructured":"Ogasawara M, Maruko I, Sugano Y, Ojima A, Sekiryu T, Iida T (2012) Retinal and choroidal thickness changes following intravitreal ranibizumab injection for exudative age-related macular degeneration. Nippon Ganka Gakkai Zasshi 116(7):643\u2013649","journal-title":"Nippon Ganka Gakkai Zasshi"},{"issue":"1","key":"6278_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00347-019-0911-5","volume":"117","author":"AD Abdin","year":"2020","unstructured":"Abdin AD, Suffo S, Bischoff-Jung M, Daas L, Pattm\u00f6ller M, Seitz B (2020) Advantages of a designated IVI center for a German university eye hospital. Ophthalmologe 117(1):50\u201357. https:\/\/doi.org\/10.1007\/s00347-019-0911-5","journal-title":"Ophthalmologe"},{"issue":"6","key":"6278_CR15","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1097\/IAE.0000000000003439","volume":"42","author":"R Serra","year":"2022","unstructured":"Serra R, Coscas F, Cabral D et al (2022) Polypoidal choroidal neovascularization versus Type 1 choroidal neovascularization in age-related macular degeneration: a fractal analysis study. Retina 42(6):1005\u20131011","journal-title":"Retina"},{"issue":"9","key":"6278_CR16","doi-asserted-by":"publisher","first-page":"5040","DOI":"10.1167\/iovs.15-1649","volume":"6","author":"B Chae","year":"2015","unstructured":"Chae B, Jung JJ, Mrejen S, Gallego-Pinazo R, Yannuzzi NA, Patel SN, Chen CY, Marsiglia M, Boddu S, Freund KB (2015) Baseline predictors for good versus poor visual outcomes in the treatment of neovascular age-related macular degeneration with intravitreal anti-VEGF therapy. Invest Ophthalmol Vis Sci 6(9):5040\u20135047. https:\/\/doi.org\/10.1167\/iovs.15-1649","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"6278_CR17","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3390\/jcm4071380","volume":"4","author":"S Mrejen","year":"2015","unstructured":"Mrejen S, Jung JJ, Chen C, Patel SN, Gallego-Pinazo R, Yannuzzi N, Xu L, Marsiglia M, Boddu S, Freund KB (2015) Long-term visual outcomes for a treat and extend anti-vascular endothelial growth factor regimen in eyes with neovascular age-related macular degeneration. J Clin Med 4(7):1380\u20131402. https:\/\/doi.org\/10.3390\/jcm4071380","journal-title":"J Clin Med"},{"key":"6278_CR18","doi-asserted-by":"publisher","first-page":"860784","DOI":"10.3389\/fphar.2022.860784","volume":"13","author":"AD Abdin","year":"2022","unstructured":"Abdin AD, Aljundi W, El Jawhari K, Suffo S, Weinstein I, Seitz B (2022) First year real life experience with intravitreal brolucizumab for treatment of refractory neovascular age-related macular degeneration. Front Pharmacol 13:860784. https:\/\/doi.org\/10.3389\/fphar.2022.860784","journal-title":"Front Pharmacol"},{"key":"6278_CR19","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2147\/DDDT.S115121","volume":"10","author":"S Yang","year":"2016","unstructured":"Yang S, Zhao J, Sun X (2016) Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther 10:1857\u20131867","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"6278_CR20","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1097\/IAE.0000000000001637","volume":"38","author":"CS Lee","year":"2018","unstructured":"Lee CS, Kim AJ, Baughman D et al (2018) Visual acuity improvement when switching from ranibizumab to aflibercept is not sustained. Retina 38(5):951\u2013956","journal-title":"Retina"},{"issue":"7","key":"6278_CR21","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1007\/s12325-019-00971-0","volume":"36","author":"T Empeslidis","year":"2019","unstructured":"Empeslidis T, Storey M, Giannopoulos T, Konidaris V, Tranos PG, Panagiotou ES, Voudouragkaki IC, Konstas AG (2019) How successful is switching from bevacizumab or ranibizumab to aflibercept in age-related macular degeneration? A systematic overview. Adv Ther 36(7):1532\u20131548. https:\/\/doi.org\/10.1007\/s12325-019-00971-0","journal-title":"Adv Ther"},{"issue":"5","key":"6278_CR22","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3390\/cells10051049","volume":"10","author":"JO Wallsh","year":"2021","unstructured":"Wallsh JO, Gallemore RP (2021) Anti-VEGF-resistant retinal diseases: a review of the latest treatment options. Cells 10(5):1049","journal-title":"Cells"},{"issue":"4","key":"6278_CR23","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1136\/bjophthalmol-2019-314251","volume":"104","author":"RP Gale","year":"2020","unstructured":"Gale RP, Pearce I, Eter N et al (2020) Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. Br J Ophthalmol 104(4):493\u2013499","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"6278_CR24","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.ophtha.2020.02.027","volume":"127","author":"S Kiss","year":"2020","unstructured":"Kiss S, Campbell J, Almony A, Shih V, Serbin M, LaPrise A, Wykoff CC (2020) Management and outcomes for neovascular age-related macular degeneration: analysis of United States electronic health records. Ophthalmology 127(9):1179\u20131188. https:\/\/doi.org\/10.1016\/j.ophtha.2020.02.027","journal-title":"Ophthalmology"},{"issue":"9","key":"6278_CR25","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1038\/s41433-022-02253-6","volume":"37","author":"J Siktberg","year":"2023","unstructured":"Siktberg J, Kim SJ, Sternberg P Jr, Patel S (2023) Effectiveness of bevacizumab step therapy for neovascular age-related macular degeneration. Eye (Lond) 37(9):1844\u20131849. https:\/\/doi.org\/10.1038\/s41433-022-02253-6","journal-title":"Eye (Lond)"},{"key":"6278_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ajo.2019.03.001","volume":"204","author":"A Invernizzi","year":"2019","unstructured":"Invernizzi A, Nguyen V, Teo K, Barthelmes D, Fung A, Vincent A, Gillies M (2019) Five-year real-world outcomes of occult and classic choroidal neovascularization: data from the Fight Retinal Blindness! Project. Am J Ophthalmol 204:105\u2013112. https:\/\/doi.org\/10.1016\/j.ajo.2019.03.001","journal-title":"Am J Ophthalmol"},{"issue":"14","key":"6278_CR27","doi-asserted-by":"publisher","first-page":"4862","DOI":"10.3390\/jcm12144862","volume":"12","author":"AD Abdin","year":"2023","unstructured":"Abdin AD, Devenijn M, Fulga R, Langenbucher A, Seitz B, Kaymak H (2023) Prevalence of geographic atrophy in advanced age-related macular degeneration (AMD) in daily practice. J Clin Med 12(14):4862. https:\/\/doi.org\/10.3390\/jcm12144862","journal-title":"J Clin Med"},{"issue":"6","key":"6278_CR28","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ophtha.2017.12.026","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Tuomi LL, Ding B, Fung AE, Hopkins JJ (2018) Macular atrophy in the HARBOR Study for neovascular age-related macular degeneration. Ophthalmology 125(6):878\u2013886. https:\/\/doi.org\/10.1016\/j.ophtha.2017.12.026","journal-title":"Ophthalmology"},{"issue":"5","key":"6278_CR29","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.ophtha.2010.09.012","volume":"118","author":"SE Chung","year":"2011","unstructured":"Chung SE, Kang SW, Lee JH, Kim YT (2011) Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology 118(5):840\u2013845. https:\/\/doi.org\/10.1016\/j.ophtha.2010.09.012","journal-title":"Ophthalmology"},{"key":"6278_CR30","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ajo.2015.12.024","volume":"164","author":"DS Ting","year":"2016","unstructured":"Ting DS, Ng WY, Ng SR, Tan SP, Yeo IY, Mathur R, Chan CM, Tan AC, Tan GS, Wong TY, Cheung CM (2016) Choroidal thickness changes in age-related macular degeneration and polypoidal choroidal vasculopathy: a 12-month prospective study. Am J Ophthalmol 164:128\u201336.e1. https:\/\/doi.org\/10.1016\/j.ajo.2015.12.024","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"6278_CR31","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1080\/02713683.2019.1600195","volume":"44","author":"S Inan","year":"2019","unstructured":"Inan S, Baysal Z, Inan UU (2019) Long-term changes in submacular choroidal thickness after intravitreal ranibizumab therapy for neovascular age-related macular degeneration: 14-mo follow-up. Curr Eye Res 44(8):908\u2013915. https:\/\/doi.org\/10.1080\/02713683.2019.1600195","journal-title":"Curr Eye Res"},{"issue":"6","key":"6278_CR32","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s00417-012-2199-x","volume":"251","author":"W Rahman","year":"2013","unstructured":"Rahman W, Chen FK, Yeoh J, da Cruz L (2013) Enhanced depth imaging of the choroid in patients with neovascular age-related macular degeneration treated with anti-VEGF therapy versus untreated patients. Graefes Arch Clin Exp Ophthalmol 251(6):1483\u20131488. https:\/\/doi.org\/10.1007\/s00417-012-2199-x","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"6278_CR33","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3980\/j.issn.2222-3959.2015.04.38","volume":"8","author":"C \u00dcnl\u00fc","year":"2015","unstructured":"\u00dcnl\u00fc C, Erdogan G, Onal Gunay B, Sezgin Akcay BI, Kardes E (2015) Subfoveal choroidal thickness changes after intravitreal bevacizumab therapy for neovascular age-related macular degeneration. Int J Ophthalmol 8(4):849\u2013851. https:\/\/doi.org\/10.3980\/j.issn.2222-3959.2015.04.38","journal-title":"Int J Ophthalmol"},{"issue":"3","key":"6278_CR34","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","volume":"26","author":"J Shahar","year":"2006","unstructured":"Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, Johnson PT, Fisher SK, Perlman I, Loewenstein A (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26(3):262\u2013269. https:\/\/doi.org\/10.1097\/00006982-200603000-00002","journal-title":"Retina"},{"issue":"4","key":"6278_CR35","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.exer.2007.05.008","volume":"85","author":"J Lowe","year":"2007","unstructured":"Lowe J, Araujo J, Yang J, Reich M, Oldendorp A, Shiu V, Quarmby V, Lowman H, Lien S, Gaudreault J, Maia M (2007) Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 85(4):425\u2013430. https:\/\/doi.org\/10.1016\/j.exer.2007.05.008","journal-title":"Exp Eye Res"},{"issue":"3","key":"6278_CR36","doi-asserted-by":"publisher","first-page":"H1054","DOI":"10.1152\/ajpheart.1998.274.3.H1054","volume":"274","author":"JD Hood","year":"1998","unstructured":"Hood JD, Meininger CJ, Ziche M, Granger HJ (1998) VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 274(3):H1054\u2013H1058. https:\/\/doi.org\/10.1152\/ajpheart.1998.274.3.H1054","journal-title":"Am J Physiol"},{"issue":"3","key":"6278_CR37","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ajo.2003.09.042","volume":"137","author":"HE Grossniklaus","year":"2004","unstructured":"Grossniklaus HE, Green WR (2004) Choroidal neovascularization. Am J Ophthalmol 137(3):496\u2013503. https:\/\/doi.org\/10.1016\/j.ajo.2003.09.042","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"6278_CR38","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1097\/IAE.0000000000001766","volume":"38","author":"JG Christenbury","year":"2018","unstructured":"Christenbury JG, Phasukkijwatana N, Gilani F, Freund KB, Sadda S, Sarraf D (2018) Progression of macular atrophy in eyes with type 1 neovascularization and age-related macular degeneration receiving long-term intravitreal anti\u2013vascular endothelial growth factor therapy: an optical coherence tomographic angiography analysis. Retina 38(7):1276\u20131288. https:\/\/doi.org\/10.1097\/IAE.0000000000001766","journal-title":"Retina"},{"issue":"5","key":"6278_CR39","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.ajo.2014.01.019","volume":"157","author":"HM Kang","year":"2014","unstructured":"Kang HM, Kwon HJ, Yi JH, Lee CS, Lee SC (2014) Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration. Am J Ophthalmol 157(5):1013\u20131021. https:\/\/doi.org\/10.1016\/j.ajo.2014.01.019","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"6278_CR40","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.ophtha.2020.03.031","volume":"127","author":"SR Sadda","year":"2020","unstructured":"Sadda SR, Abdelfattah NS, Lei J, Shi Y, Marion KM, Morgenthien E, Gune S, Balasubramanian S (2020) Spectral-domain OCT analysis of risk factors for macular atrophy development in the HARBOR Study for neovascular age-related macular degeneration. Ophthalmology 127(10):1360\u20131370. https:\/\/doi.org\/10.1016\/j.ophtha.2020.03.031","journal-title":"Ophthalmology"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06278-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-023-06278-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06278-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T09:06:31Z","timestamp":1707123991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-023-06278-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,21]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["6278"],"URL":"https:\/\/doi.org\/10.1007\/s00417-023-06278-9","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,21]]},"assertion":[{"value":"13 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Medical Association of Saarland, Germany (Nr. 123\/20). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of retrospective study, formal consent is not required. However, all patients provided written informed consent before each IVI, as usual approach in our clinical practice.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"\u2022 <i>Financial interests:<\/i> Abdin AD has received speaker and consultant honoraria from Novartis and Bayer Company. Other authors declare they have no financial interests.\u2022 <i>Non-financial interests:<\/i> none.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}